Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-25-107607
Filing Date
2025-11-07
Accepted
2025-11-07 16:00:27
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 27235
  Complete submission text file 0001213900-25-107607.txt   29047
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Subject) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88651 | Film No.: 251462437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830 475-208-3178
Soleus Private Equity Fund III, L.P. (Filed by) CIK: 0001955982 (see all company filings)

EIN.: 880637097 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A